Management of Lipids in the Prevention of Cardiovascular Events
- 1 February 2008
- journal article
- review article
- Published by Annual Reviews in Annual Review of Medicine
- Vol. 59 (1), 79-94
- https://doi.org/10.1146/annurev.med.59.121206.112237
Abstract
Lipid-modifying therapy has been proven to significantly reduce cardiovascular events and total mortality. Most of the data have come from statin trials. Statin therapy is generally well-tolerated and safe, and for patients who are at higher than average risk of cardiovascular disease, the benefit of lipid-modifying therapy far exceeds the risk. Careful risk assessment is a critical component of effective lipid-modifying therapy. In the foreseeable future, low-density lipoprotein cholesterol (LDL-C) will remain the primary therapeutic target, and combination therapy is likely to become the norm. The major questions are how low to treat and how to achieve increasingly aggressive targets in lipid-lowering therapy. Many patients on LDL-lowering therapy continue to have abnormalities of the triglyceride–high-density lipoprotein (TG-HDL) axis, so additional drug therapy is often considered for such patients. In this review, we briefly discuss new developments in cardiovascular risk assessment, then discuss recent developments in treatment to reduce LDL, and finally discuss current concepts regarding therapy targeting the TG-HDL axis.Keywords
This publication has 57 references indexed in Scilit:
- Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in WomenJAMA, 2007
- Metabolic Syndrome: Focus on DyslipidemiaObesity, 2006
- Atherothrombosis and High-Risk PlaqueJournal of the American College of Cardiology, 2005
- Atherothrombosis and High-Risk PlaqueJournal of the American College of Cardiology, 2005
- Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation, 2004
- The Metabolic SyndromeCirculation, 2003
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsNew England Journal of Medicine, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Prevalence of the Metabolic Syndrome Among US AdultsJAMA, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001